新型长效毒蕈碱拮抗剂revefenacin  

Revefenacin: a novel long-acting muscarinic antagonist

作　　者：王艺花 罗颖[1] 刘相奎[1] WANG Yi-hua;LUO Ying;LIU Xiang-kui(State Key Laboratory of Innovative Drugs and Pharmaceutical Technology,China State Institute of Pharmaceutical University,Shanghai 201203,China)

机构地区：[1]中国医药工业研究总院上海医药工业研究院,创新药物与制药工艺国家重点实验室,上海201203

出　　处：《中国新药杂志》2020年第7期721-725,共5页Chinese Journal of New Drugs

摘　　要：revefenacin(商品名Yupelri■,曾用名TD-4208)是一种新型长效毒蕈碱拮抗剂,用于慢性阻塞性肺疾病患者的维持治疗,2018年11月9日由FDA批准上市,每日一次雾化治疗,方便有效地缓解症状。本文对revefenacin的作用机制、药效学、药动学、药物相互作用、临床评价和安全性进行综述。Revefenacin(Yupelri■, TD-4208) is a novel long-acting muscarinic antagonist(LAMA) for maintenance therapy in patients with chronic obstructive pulmonary disease. It was approved by the FDA on November 9, 2018. Symptoms can be easily and effectively relieved by using revefenacin for atomization therapy only once daily. This article reviews the mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, clinical evaluation and safety of revefenacin.

关 键 词：revefenacin 慢性阻塞性肺疾病 长效毒蕈碱拮抗剂 雾化治疗 

分 类 号：R974[医药卫生—药品]